Home > Boards > US Listed > Biotechs > Gemini Therapeutics (GMTX)

Best to wait for a base build here

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
oxnous Member Profile
 
Followed By 44
Posts 2,691
Boards Moderated 1
Alias Born 11/12/10
160x600 placeholder
Lightstone Ventures Raises $375 Million Fund PR Newswire (US) - 9/14/2021 7:00:00 AM
Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics Business Wire - 9/10/2021 8:30:00 AM
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual Business Wire - 9/9/2021 7:00:00 AM
Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Business Wire - 9/7/2021 7:00:00 AM
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit Business Wire - 8/30/2021 7:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 8/17/2021 7:15:35 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 8/17/2021 7:11:34 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/17/2021 7:06:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/17/2021 7:01:32 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/12/2021 10:34:31 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/12/2021 10:20:35 AM
Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Business Wire - 8/12/2021 7:00:00 AM
Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference Business Wire - 8/10/2021 7:00:00 AM
Gemini Therapeutics shares continue fall following phase 2 AMD study results Seeking Alpha - 6/23/2021 2:56:14 PM
Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Seco... Business Wire - 6/22/2021 4:05:00 PM
Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference Business Wire - 5/26/2021 7:00:00 AM
Gemini Therapeutics EPS misses by $0.25 Seeking Alpha - 5/13/2021 8:34:09 AM
Gemini Therapeutics completes enrollment in mid-stage wet AMD trial Seeking Alpha - 5/13/2021 7:51:15 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2021 7:36:01 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/13/2021 7:31:34 AM
Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update Business Wire - 5/13/2021 7:01:00 AM
Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of W... Business Wire - 5/13/2021 7:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 5/12/2021 4:04:03 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2021 4:02:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2021 4:03:32 PM
oxnous   Thursday, 06/24/21 01:08:23 PM
Re: None
Post # of 5 
Best to wait for a base build here followed by an increase in average trading volume. jmo

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences